Biocompatible Polymers: Fascinating Materials for Drug Delivery Applications

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 30 November 2026 | Viewed by 2901

Special Issue Editors


E-Mail Website
Guest Editor
Group for Biomedical Engineering and Nanobiotechnology, Institute of Technical Sciences of the Serbian Academy of Sciences and Arts (SASA), Kneza Mihaila 35/IV, 11000 Belgrade, Serbia
Interests: biopolymers; biomaterials; controlled drug delivery; nanomaterials; nanomedicine; biomedical research; synthesis and characterization of biocompatible micro and nanoparticles; tissue engineering
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Advanced Materials Department, Jožef Stefan Institute, Jamova 39, 1000 Ljubljana, Slovenia
Interests: degradation of polymers; inorganic/metal/polymer components; identification and composition; surface properties; in vitro tests for drug release; in vitro stability tests of biomaterials
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue will highlight recent advances in the design, synthesis, characterization, and application of biocompatible polymers in drug delivery. These versatile materials offer controlled drug release, improved bioavailability, and targeted therapeutic effects while ensuring biocompatibility and biodegradability. This issue aims to bring together cutting-edge research on novel polymer-based carriers, including hydrogels, nanospheres, micelles, and smart polymeric systems, exploring their potential in personalized medicine and regenerative therapies. Contributions focusing on innovative polymer formulations, in vitro and in vivo evaluations, and translational research for clinical applications are highly encouraged.

Dr. Magdalena Stevanović
Dr. Marija Vukomanović
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biocompatible polymers
  • drug delivery systems
  • polymeric micro- and nanoparticles
  • controlled and/or targeted drug delivery
  • biodegradable polymers
  • smart drug carriers
  • nanomedicine
  • biomedical applications
  • encapsulation efficiency
  • stimuli-responsive polymers
  • pharmacokinetics and bioavailability

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

33 pages, 1373 KB  
Review
PLGA-Based Co-Delivery Nanoformulations: Overview, Strategies, and Recent Advances
by Magdalena M. Stevanović, Kun Qian, Lin Huang and Marija Vukomanović
Pharmaceutics 2025, 17(12), 1613; https://doi.org/10.3390/pharmaceutics17121613 - 15 Dec 2025
Cited by 13 | Viewed by 2384
Abstract
Poly (lactic-co-glycolic acid) (PLGA) is a widely used copolymer with applications across medical, pharmaceutical, and other industrial fields. Its biodegradability and biocompatibility make it one of the most versatile polymers for nanoscale drug delivery. The present review addresses current knowledge and recent advances [...] Read more.
Poly (lactic-co-glycolic acid) (PLGA) is a widely used copolymer with applications across medical, pharmaceutical, and other industrial fields. Its biodegradability and biocompatibility make it one of the most versatile polymers for nanoscale drug delivery. The present review addresses current knowledge and recent advances in PLGA-based co-delivery nanoformulations with a special reference to design strategies, functional mechanisms, and translational potential. Conventional and advanced fabrication methods, the structural design of PLGA-based nanocarriers, approaches to scale-up and reproducibility, classification of co-delivery types, mechanisms governing drug release, surface modification and functionalization are all discussed. Special attention is given to PLGA-based co-delivery systems, encompassing drug–drug, drug–gene, gene–gene and multi-modal combinations, supported by recent studies demonstrating synergistic therapeutic outcomes. The review also examines clinical translation efforts and the regulatory landscape for PLGA-based nanocarriers. Unlike most existing reviews that typically focus either on PLGA fundamentals or on co-delivery approaches in isolation, this article bridges these domains by providing an integrated, comparative analysis of PLGA-based co-delivery systems and elucidating a critical gap in linking design strategies with translational requirements. In addition, by emphasising the relevance of PLGA-based co-delivery for combination therapies, particularly in cancer and other complex diseases, the review highlights the strong clinical and translational potential of these platforms. Key challenges, such as reproducibility, large-scale manufacturing, and complex regulatory pathways, are discussed alongside emerging trends and future perspectives. Taken together, this review positions PLGA-based co-delivery strategies as a critical driver for advancing precision therapeutics and shaping the future landscape of nanomedicine. Full article
Show Figures

Graphical abstract

Back to TopTop